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Figure 2. HY-Ab 3m post-HCT & disease replace in F/M HCT with TLI-ATG
(MDS and CLL were not included).
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in M->F, P<0.01 in each), while no impact of sex-mismatch
on relapse was observed in the MAC or RIC groups (Fig 1).
Finally, in the TLI-ATG group, sex-mismatched transplant
was signiﬁcantly associated with superior OS (HR 0.69 in F-
>M, P¼0.037; HR 0.61 in M->F, P¼0.014), while F->M
transplant was signiﬁcantly associatedwith inferior OS in the
MAC group (HR 1.59, P¼0.018) and no improvement in OS in
the RIC group (HR 1.31, P¼0.36) (Fig 2).
In the TLI-ATG group, the beneﬁt of sex-mismatched HCT
on OS seems due to the reduced relapse rate. We previously
reported HY-Ab response post-HCT was associated with
chronic GVHD as a representative of allo-Ab response
(Nakasone et al. ASH 2013). We then hypothesized that HY-
Ab response 3m post-HCT could predict reduced relapse in F-
>MHCTwith TLI-ATG. Relapse incidence at 2 years post-HCT
was higher in the recipients who had no HY-Ab response at
3m post-HCT vs. those who did (49% vs. 26%, P¼0.037, Fig 2).
Multivariate analysis corroborated that the detection of HY-
antibodies 3m post-HCT was signiﬁcantly associated with
reduced relapse in F->M HCT with TLI-ATG [HR 0.29,
P¼0.039].
Conclusion: We conclude that the beneﬁts and risks of sex-
mismatch differ according to conditioning intensity/strategy,
and is the ﬁrst reported evidence that sex-mismatched
transplant might preferably be selected in TLI-ATG, while
avoided in MAC transplantation.496
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Acute graft versus host disease (GVHD) is a major cause of
morbidity and mortality after allogeneic hematopoietic celltransplantation (HCT). Based on established consensus
grading criteria, a correlation between clinical grading and
survival has been well established. A histologic grading sys-
tem for acute GVHD of the skin and gastrointestinal (GI) tract
has also been well established, and is routinely used by pa-
thologists when reporting this diagnosis. There are limited
data, however, on the correlation of the histologic grade with
clinical grade and its ability to predict outcome. We thus
undertook this retrospective analysis to further evaluate the
impact of histologic grade on treatment response and
outcome. Among 503 consecutive patients who underwent
allogeneic HCT from 2005-2013, we identiﬁed 234 patients
with 303 episodes where tissue biopsies (skin and GI)
conﬁrmed presence of acute GVHD. There were 140 (46%) GI
and 163 (54%) skin biopsies. Histologic grade was analyzed
and correlated with clinical grade of GVHD, day 28 treatment
response, and outcome. Although both GI and skin histology
were signiﬁcantly correlated with overall clinical grade
(p<0.001), there was a stronger association with GI histo-
logic grade (R¼0.559) compared to skin (R¼0.315). GI his-
tologic grade was lower than clinical grade in 64% of GVHD
episodes, the same in 15%, and higher in 21% of occurrences.
In contrast, skin histologic grade was lower than clinical
grade in only 4% of GVHD episodes, the same in 17% and
higher in 79%. Overall histologic grade, independent of tissue
site, and overall clinical grade were both signiﬁcantly asso-
ciated with day 28-treatment response. 71% (n¼70) of pa-
tients with histologic grade 1 GVHD had a complete response
(CR) to therapy; whereas only 6% (n¼1) with histologic grade
4 GVHD achieved a CR. In univariable analysis, worst GVHD
by histologic grade was predictive of non-relapse (HR 1.67,
95% CI 1.30-2.14, p<0.001) and overall mortality (HR 1.40,
95% CI 1.15-1.70, p<0.001). Similarly, overall clinical grade
was predictive of non-relapse (HR 1.41, 95% CI 1.02-1.93,
p¼0.036) and overall mortality (HR 1.60, 95% CI 1.29-1.99,
p<0.001). In multivariable analysis, overall clinical grade
remained the strongest predictor of non-relapse (HR 1.41,
95% CI 1.02-1.94, p¼0.037) and overall mortality (HR 1.65,
95% CI 1.32-2.06, p<0.001), while histologic grade became
non-signiﬁcant. In conclusion, histologic GVHD grade has
some correlation with clinical grading and treatment
response, and may play a role in further supporting the
severity of GVHD, particularly in speciﬁc tissues. Overall
clinical grade, however, remains the strongest predictor of
mortality post-transplant.497
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Introduction: NIH Consensus criteria for diagnosis of
chronic GVHD (cGVHD) have been examined in several
retrospective studies evaluating cGVHD and its comparison
to other GVHD syndromes. There is less data regarding late
aGVHD with onset beyond 100 days after HCT. We evaluated
a cohort of allogeneic HCT recipients from 2007 to 2012 who
developed persistent, recurrent or denovo late aGVHD.
Patients and Methods: 75 patients (median age 50.7 years)
were classiﬁed as late aGVHD. Donors were HLA-identical
sibling in 41.3%, UCB in 45.3%, URD in 13.3%. 46.7% recipients
Table
Comparison of late aGVHD categories with classic aGVHD
De-novo
n¼7
Persistent
n¼39
Recurrent
n¼29
Classic
Acute
n¼268
Median time
to onset,
range
155 (101-262) 100 143 (102-342) 36 (7-180)
2 year overall
survival
after onset
(95% CI)
83% (27-97) 45% (28-60) 74% (53-87) 50% (44-57)
1 year NRM
after onset
0% 26% (12-40) 14% (4-26) 24% (19-29)
Progression
to cGVHD
within 2
years of
onset
42% (16-75) 51% (36-66) 38% (23-56) 31% (26-37)
Figure 2. Cumulative incidence of outcomes following late aGVHD
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received a reduced intensity conditioning. Median follow up
was 4 years.
Results: The cumulative incidence of any late aGVHD was
14.7% (95% CI: 11.6-17.8) and grade II-IV late aGVHD was
11.7% (95% CI 8.7-14.7) at one year (Figure 1). 52% had
persistent (deﬁned as active aGVHD that persisted without
resolution after 100 days), 39% had recurrent (aGVHD that
recurred following resolution after 100 days) and 9% had de-
novo late aGVHD. Median time to onset was 155 days for de-
novo late aGVHD, and 143 days for recurrent late aGVHD
(Table). Persistent late aGVHD was considered to have a time
of onset of 100 days. Outcomes were estimated from onset of
late aGVHD (Table). One and 2 year overall survival was 73%
(95% CI 63-84) and 59% (95% CI 49-72). Figure 2 shows the
cumulative incidences of outcomes after late aGVHD. Pro-
gression to cGVHD or overlap syndrome was seen in 45%
(95% CI 35-57) by two years. Durable discontinuation of
immunosuppression (IS) was achieved in 15%, 41% and 57% of
persistent, recurrent and de-novo late aGVHD. In multivar-
iate analysis, PBSC [HR 2.1, 95% CI: 1.2-3.5, p¼0.01] and
myeloablative conditioning [HR 1.8, 95% CI: 1.0-3.2, p¼0.04)]
were associated with higher risks of developing late aGVHD.
Conclusions: We present results of clinical presentation and
outcomes in patients with late aGVHD. Amongst patients
with late aGVHD, durable discontinuation of IS was seen in
only 15% of those with persistent late aGVHD, indicating
need for intensiﬁed therapy in this group. PBSC and mye-
loablative conditioning were associated with a higher risk of
developing late aGVHD. Modulation of these risk factors
(such as intensiﬁed or longer duration of GVHD prophylaxis
in these higher risk groups) may allow reduced risks and
improved transplant outcomes.Figure 1. Cumulative Incidence of Grade II-IV late aGVHD498
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Acute and chronic graft vs host disease remains one of the
largest challenges in allogeneic stem cell transplantation.
Diagnosis and staging of GVHD is largely clinically based:
physical exam ﬁndings, laboratory data, combined with
pathologic conﬁrmation. Typical radiologic ﬁndingsmay aide
in diagnosis as well. Recent radiographs of GVHD patients are
reviewed. Notable ﬁndings in acute GVHD of the gut included
edematous bowel wall thickening and ﬂuid ﬁlled bowel.
Some patients have exhibited hyper enhancing gut mucosa
on contrast enhanced CT. PET scans may show diffuse
increased metabolic activity in affected areas. Chest CT
ﬁndings in chronic GVHD patients commonly include ground
glass opacities in the lungs, both peribronchial and para-
septal. Later advanced ﬁndings may classically include
bronchiectasis. MRI ﬁndings in sclerotic type GVHD may
include edema and enhancement within deep fascial planes.
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The acute graft versus host disease (aGVHD) is the most
common complication subsequent to allogeneic hematopoi-
etic progenitor cell donor match HLA (Human Leukocyte An-
tigen), occurring in 30-50%. In hematopoietic progenitor
transplantation (HSCT) there are other genetic factors such as
minor histocompatibility antigens and cytokines. The HLA-C
locus has been divided into two groups according to the amino
acid at position 80; this variation is important for the type of
KIR (killer cell Ig-like receptor). The C1 group contains a lysine
at position 80 and includes Cw2, -4 alleles -, - 5, -6, -15. The
group includes C2 Cw1, -3, -7, -8 alleles contains an asparagine
at position 80 alleles of the C1 group for KIR2DL1 and KIR2DS1
receptor and group C2 alleles bind to KIR2DL2 receptors bind
and KIR2DL3. The interaction of the different alleles of HLA-C
locus with KIR receptors expressed on NK cells cytotoxic ac-
tivity changes which inﬂuence the risk for development of
aGVHD.
